OPTHF - Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference | Benzinga
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a Presenting Sponsor at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference. The event is scheduled to take place in Boston, Massachusetts on May 23-24, 2024.
The 4th Annual Psychedelic Therapeutics and Drug Development Conference convenes renowned researchers and esteemed leaders from academia, industry, non-profit organizations, and government sectors to explore the challenges and opportunities inherent in the research and development of psychedelic therapies for various health conditions with significant unmet needs.
The conference presents a tremendous opportunity for Optimi to showcase its strength as a tier one GMP psychedelics pharmaceutical manufacturer committed to producing high-quality, GMP products that adhere to the strictest standards of safety and efficacy.
"We have predominantly maintained a low profile over the last three years while developing and enhancing our operational and quality assurance capabilities," stated Bill Ciprick, CEO of Optimi, speaking from the company's 10,000 sq ft cultivation and formulation facility in Princeton, British Columbia. "We believe this conference serves as an excellent platform for us to engage with key stakeholders, exchange ideas, and drive innovation in the field of psychedelic therapeutics," he added.
Ciprick will deliver a presentation on Thursday, May 23, 2024, at 10:50 a.m. EST. His session, titled "Manufacturing the Future of GMP Psychedelics: What Researchers, Clinicians, and Drug Developers Need to ...